Table 4. Multivariate analyses of the correlation between SNPs and treatment efficacy at 3 months after radiotherapy.
| SNPs | Genotypes | Primary tumor efficacy1 (n=128) | Lymph node efficacy1 (n=108) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CR2 | Non-CR2 | OR | 95%CI | P | CR2 | Non-CR2 | OR | 95%CI | P | ||
| XRCC1 rs25489 | GG:GA | 84/28/6 | 7/3/0 | 1.351 | 0.243-7.502 | 0.731 | 71/22/4 | 8/3/0 | 1.150 | 0.225-5.881 | 0.866 |
| GG:AA | - | - | - | - | - | - | |||||
| GG:(GA+AA) | 1.032 | 0.196-5.425 | 0.970 | 1.052 | 0.208-5.310 | 0.951 | |||||
| (GG+GA):AA | - | - | - | - | - | - | |||||
| OGG1 rs1052133 | CC:CG | 38/58/22 | 6/4/0 | 0.535 | 0.122-2.334 | 0.405 | 35/44/18 | 2/5/4 | 1.838 | 0.296-11.401 | 0.514 |
| CC:GG | - | - | - | 3.795 | 0.555-25.975 | 0.174 | |||||
| CC:(CG+GG) | 0.335 | 0.079-1.427 | 0.139 | 2.446 | 0.455-13.154 | 0.297 | |||||
| (CC+CG):GG | - | - | - | 2.617 | 0.588-11.656 | 0.207 | |||||
| APE(X)1 rs1130409 | TT:TG | 40/65/13 | 5/4/1 | 0.480 | 0.096-2.407 | 0.372 | 32/55/10 | 5/4/2 | 0.574 | 0.118-2.802 | 0.493 |
| TT:GG | 0.479 | 0.037-6.166 | 0.572 | 1.116 | 0.141-8.859 | 0.917 | |||||
| TT:(TG+GG) | 0.479 | 0.106-2.166 | 0.339 | 0.702 | 0.171-2.875 | 0.623 | |||||
| (TT+TG):GG | 0.666 | 0.057-7.756 | 0.745 | 1.375 | 0.184-10.300 | 0.756 | |||||
1 Adjusted for age, gender, drinking, smoking, family history, BMI, TNM stage and clinical stage, treatment and EBV-DNA.
2 Wild homozygote / heterozygote / mutant homozygote.
SNPs, single nucleotide polymorphisms; CR, complete remission; OR, odds ratio; 95%CI, 95% confidence interval.
P values < 0.05 are shown in bold.